William Blair & Company
BCRX icon

William Blair & Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

William Blair & Company’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$48K – 1719
2020
Q2 		$48K Buy
+10,000
New +$39.9K ﹤0.01% 1448

Other funds holding BCRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

William Blair & Company's BCRX Position: Q3 2020 in Review

William Blair & Company sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2020, closing a stake of 10,000 shares — an estimated $48K sold.

William Blair & Company first reported a position in BCRX in Q2 2020 and held it in 1 quarter. The position peaked at $48K in Q2 2020. 154 funds tracked by Wall St. Rank hold BCRX as of Q3 2020.

  • William Blair & Company reported no remaining BioCryst Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • William Blair & Company sold 10,000 BioCryst Pharmaceuticals shares in Q3 2020, an estimated $48K.
  • William Blair & Company first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • William Blair & Company's BioCryst Pharmaceuticals position peaked at $48K in Q2 2020.
  • 154 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2020.

Based on William Blair & Company's 13F filing for Q3 2020, filed 6 Nov 2020.